FibroGen, Inc. (NASDAQ:FGEN) Files An 8-K Other Events
Item8.01
| Other Events |
On March31, 2017, FibroGen, Inc. issued a press release in which
it reported approval by the China Food and Drug Administration of
its clinical trial application in China for a Phase 2/3 pivotal
trial of roxadustat in anemia associated with lower risk
myelodysplastic syndromes. The Company received notification of
the approval on March21, 2017.
A copy of such press release is furnished as Exhibit99.1 to this
report and is incorporated herein by reference.
| Item9.01 | Financial Statements and Exhibits. |
| (d) | Exhibits |
|
Exhibit No. |
Description |
|
| 99.1 |
Press Release titled FibroGen Announces China FDA Approval of CTA to Conduct Pivotal Phase 2/3 Clinical Trial of Roxadustat in Anemia Associated with Lower Risk MDS dated March31, 2017 |
About FibroGen, Inc. (NASDAQ:FGEN)
FibroGen, Inc. is a research-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200. FG-4592 is an oral small molecule inhibitor of hypoxia-inducible factor-prolyl hydroxylases (HIF-PHs), which acts by stimulating the body’s natural pathway of erythropoiesis or red blood cell production. FG-4592 is in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD). FG-3019 is a monoclonal antibody, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), pancreatic cancer, Duchenne muscular dystrophy (DMD) and liver fibrosis. FG-6874 is in Phase I clinical trials, and FG-5200 is a corneal implant medical device, which is in preclinical studies. FibroGen, Inc. (NASDAQ:FGEN) Recent Trading Information
FibroGen, Inc. (NASDAQ:FGEN) closed its last trading session down -0.65 at 24.80 with 318,456 shares trading hands.
